Literature DB >> 19913081

Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells.

Kiyoshi Terawaki1, Yasushi Ikarashi, Kyoji Sekiguchi, Yoichiro Nakai, Yoshio Kase.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Yokukansan (YKS) is a traditional Japanese medicine consisted of seven medicinal herbs and has been used for treatment of neurosis, insomnia, and behavioral and psychological symptoms of dementia (BPSD) in Japan. AIM OF THE STUDY: The aim of the present study is to clarify the intrinsic activity of YKS on serotonin (5-HT)1A and 5-HT2A receptors and also to determine the constituent herbs which are responsible for the effect of YKS.
MATERIALS AND METHODS: The dry powdered extracts of YKS, seven constituent herbs, and YKS-analogues which were produced by eliminating one of the constituent herbs from YKS in the manufacturing process, were used for the evaluation. Competitive binding assays for 5-HT receptors and [(35)S]GTPgammaS binding assays for the evaluation of agonistic/antagonistic activity were performed using Chinese hamster ovary cell membranes stably expressing human recombinant 5-HT1A or 5-HT2A receptors.
RESULTS: YKS (6.25-400 microg/ml) concentration-dependently inhibited the binding of [(3)H]8-OH-DPAT to 5-HT1A receptors. The IC(50) value was estimated to be 61.2 microg/ml. In contrast, YKS failed to inhibit the binding of [(3)H]ketanserin to 5-HT2A receptors. Only Uncaria hook (3.13-50 microg/ml), of the seven constituent herbal extracts, inhibited the [(3)H]8-OH-DPAT binding to 5-HT1A receptors in a concentration-dependent manner, and the IC(50) value was estimated to be 7.42 microg/ml. The extracts of YKS or Uncaria hook increased [(35)S]GTPgammaS binding to 5-HT1A receptors to approximately 50% of that of a full agonist, 5-HT. Both the competitive binding and [(35)S]GTPgammaS binding of YKS to 5-HT1A receptors were remarkably attenuated by eliminating Uncaria hook from YKS, but it was almost unchanged when one of the other constituent herbs was eliminated from YKS.
CONCLUSION: These results suggest that YKS has a partial agonistic effect on 5-HT1A receptors, which is mainly attributed to Uncaria hook. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913081     DOI: 10.1016/j.jep.2009.11.003

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  23 in total

1.  Mother/offspring co-administration of the traditional herbal remedy yokukansan during the nursing period influences grooming and cerebellar serotonin levels in a rat model of neurodevelopmental disorders.

Authors:  Katsumasa Muneoka; Makiko Kuwagata; Tetsuo Ogawa; Seiji Shioda
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

2.  The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan.

Authors:  Sachiko Imamura; Masahiro Tabuchi; Hirotaka Kushida; Akinori Nishi; Hitomi Kanno; Takuji Yamaguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2011-03-26       Impact factor: 5.046

3.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

4.  Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor.

Authors:  Toshiyuki Ueki; Akinori Nishi; Sachiko Imamura; Hitomi Kanno; Kazushige Mizoguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2012-09-12       Impact factor: 5.046

5.  An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease.

Authors:  Taku Hatano; Nobutaka Hattori; Tadaaki Kawanabe; Yasuo Terayama; Norihiro Suzuki; Yasuo Iwasaki; Toshiki Fujioka
Journal:  J Neural Transm (Vienna)       Date:  2013-10-30       Impact factor: 3.575

6.  The Kampo medicine Yokukansan (YKS) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.

Authors:  Kazuki Terada; Yukari Matsushima; Kazuhisa Matsunaga; Jiro Takata; Yoshiharu Karube; Atsushi Ishige; Koji Chiba
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

7.  Ameliorating effect of Yokukansan on the development of atopic dermatitis-like lesions and scratching behavior in socially isolated NC/Nga mice.

Authors:  Naoko Funakushi; Takuji Yamaguchi; Ju Jiang; Sachiko Imamura; Takatoshi Kuhara; Hajime Suto; Rie Ueki; Yoshio Kase; Hiroyuki Kobayashi; Hideoki Ogawa; Shigaku Ikeda
Journal:  Arch Dermatol Res       Date:  2011-03-02       Impact factor: 3.017

8.  Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study.

Authors:  Hiroyuki Kitagawa; Masaya Munekage; Kengo Ichikawa; Ian Fukudome; Eri Munekage; Yuka Takezaki; Takashi Matsumoto; Yasushi Igarashi; Haruo Hanyu; Kazuhiro Hanazaki
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

9.  The Kampo Medicine Yokukansan Decreases MicroRNA-18 Expression and Recovers Glucocorticoid Receptors Protein Expression in the Hypothalamus of Stressed Mice.

Authors:  Shoko Shimizu; Takashi Tanaka; Takashi Takeda; Masaya Tohyama; Shingo Miyata
Journal:  Biomed Res Int       Date:  2015-05-14       Impact factor: 3.411

10.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Thoyama; Kenta Murotani; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shuichi Ueno; Sachiko Ezoe; Syuzo Hoshino; Haruo Seno
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.